View article

Methods

This is a retrospective study of patients who underwent restorative proctocolectomy with IPAA who were subsequently diagnosed with CP or CDLPI and treated with tofacitinib at the University of Chicago Medicine and Mount Sinai Hospital. This study was approved by the Institutional Review Board of the University of Chicago (# 16-0061,# 15573A) and Mount Sinai Hospital (# 16-01321). We retroactively calculated Modified Pouchitis Disease Activity Index (mPDAI) 6 based on clinical symptoms and endoscopic findings described in the medical charts. Endoscopic findings were defined according to the Chicago classification of pouchitis. 7 Our definition of CDLPI included presence of fistulae, strictures involving the pouch or afferent limb, or afferent limb inflammation. 8, 9 Clinical response was defined as an improvement in clinical symptoms during tofacitinib use (≥ 2-point improvement from the baseline …